PDCD1 and familial pancreatic carcinoma: In addition, the vaccine therapy induces the adaptive immune resistance mechanisms, including the PD-1–PD-L1 pathway, indicates that the vaccine approach could prime pancreatic cancer for immune checkpoint and other immunomodulatory therapies [17].